首页> 外文期刊>Archives of dermatological research. >Matrix metalloproteinase-2 promoter variability in psoriasis.
【24h】

Matrix metalloproteinase-2 promoter variability in psoriasis.

机译:牛皮癣中基质金属蛋白酶2启动子的变异性。

获取原文
获取原文并翻译 | 示例
           

摘要

The expression of matrix metalloproteinase-2 was observed to be significantly upregulated in psoriasis. The aim of this study was to associate the DNA polymorphic variants in MMP-2 promoter gene with psoriasis and/or with psoriasis phenotypes related to psoriasis and comorbid heredity. In the total of 582 Czech Caucasian individuals (386 patients with psoriasis and 196 controls of similar age and sex distribution without personal or family history of chronic disease of the skin), four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) were detected by PCR methods. A significant association of GG genotype of -790 MMP-2 polymorphism with psoriasis was observed (Pcorr = 0.04). Although no significant case-control differences in frequency of associated GG(-1575)CC(-1306)TT(-790) MMP-2 promoter genotype were observed, the genotype was found to be significantly less frequent in patients with family history of psoriasis (close as well as distant), family history of diabetes and personal history of allergy (2/11 vs. 55/32, odds ratio (OR) for GGCCTT 0.11, 95% confidential interval 0.02-0.50, Pcorr = 0.01). The significant difference between psoriatic patients with positive anamnestic data on diabetes, psoriasis and allergy compared with psoriatic patients that have only positive family history of diabetes was also observed (2/11 vs. 38/31, P = 0.009, Pcorr = 0.04; OR 0.15, 95% CI = 0.03-0.72 for psoriatic patients with GGCCTT genotype and family history of psoriasis, diabetes and personal history of allergy). To conclude, the associated GGCCTT genotype in the promoter of MMP-2 gene was less frequent in patients with positive family history of psoriasis, diabetes and personal history of allergy compared with psoriatic patients without them (2/11 vs. 68/57, P = 0.007, Pcorr = 0.04; OR = 0.15, 95% CI = 0.03-0.72 for psoriatic patients with family history of psoriasis and diabetes and with allergy). Based on our results, we suggest that the MMP-2 located in the psoriasis susceptibility region on 16q (psoriasis susceptibility 8, PSORS8) should be considered as a gene modulator of psoriasis in specific subgroups of patients. In the future, similar genetic characteristics could contribute to the data assembly of genetic predisposition to psoriasis and could lead to therapy improvement based on time-proved individual pharmacogenetic aspects detected in psoriasis patients.
机译:观察到在牛皮癣中基质金属蛋白酶-2的表达明显上调。这项研究的目的是将MMP-2启动子基因中的DNA多态性变异体与牛皮癣和/或与牛皮癣和共病遗传相关的牛皮癣表型相关联。在总共582名捷克高加索人中(386名牛皮癣患者和196名年龄和性别分布相似,没有个人或家族慢性皮肤病史的对照),四个MMP-2启动子多态性(-1575G / A,-1306C /通过PCR方法检测T,-790T / G和-735C / T。观察到-790 MMP-2多态性的GG基因型与牛皮癣显着相关(Pcorr = 0.04)。虽然没有观察到相关的GG(-1575)CC(-1306)TT(-790)MMP-2启动子基因型频率的显着病例对照差异,但发现该基因型在有牛皮癣家族史的患者中明显较少(近距离和远距离),糖尿病家族史和个人过敏史(2/11比55/32,GGCCTT的比值比(OR)为0.11,95%的机密区间为0.02-0.50,Pcorr = 0.01)。在糖尿病,牛皮癣和变态反应阳性的银屑病患者中,与仅有糖尿病家族史阳性的银屑病患者相比,也观察到显着差异(2/11比38/31,P = 0.009,Pcorr = 0.04;或对于GGCCTT基因型和银屑病家族史,糖尿病和个人过敏史的银屑病患者,分别为0.15、95%CI = 0.03-0.72)。总之,与没有银屑病,银屑病和家族性变态反应史的银屑病患者相比,MMP-2基因启动子中相关的GGCCTT基因型的发生率要低(2/11与68/57,P =银屑病,糖尿病家族史和变态反应的银屑病患者= 0.007,Pcorr = 0.04; OR = 0.15,95%CI = 0.03-0.72)根据我们的结果,我们建议将位于16q牛皮癣易感性区域(牛皮癣易感性8,PSORS8)的MMP-2视为特定亚组患者牛皮癣的基因调节剂。将来,类似的遗传学特征可能有助于牛皮癣遗传易感性的数据收集,并可能基于在牛皮癣患者中检测到的时间已证实的个体药理学方面,导致治疗改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号